Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck

Patricia A. Tang, Lillian L. Siu, Eric X. Chen, Sebastien J. Hotte, Stephen Chia, James K Schwarz, Gregory R. Pond, Caitlin Johnson, A. Dimitrios Colevas, Timothy W. Synold, Lakshmi S. Vasist, Eric Winquist

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy. A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC). Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days. Twenty-one patients were enrolled onto this study with a target stage I sample size of 19. Of 20 evaluable patients, no objective responses were seen and stable disease > 2 cycles was observed in five patients (25%). The median time to progression was 1.4 (95% CI 1.3-2.3) months, median survival was 3.5 (95% CI 2.8-7.8) months, and 1 year overall survival was 20% (95% CI 8.3-48.1%). The most frequent attributable grades III-V adverse events were neutropenia (60% of patients) and leukopenia (55%). The pharmacokinetic profile was consistent with results from phase I studies. Archival tissues (n = 14) demonstrated low to moderate KSP expression by immunohistochemistry. In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalInvestigational New Drugs
Volume26
Issue number3
DOIs
StatePublished - Jun 1 2008

Fingerprint

Kinesin
Spindle Apparatus
Survival
Leukopenia
Neutropenia
Sample Size
Blood Cells
Appointments and Schedules
Proteins
Pharmacokinetics
Immunohistochemistry
ispinesib
Carcinoma, squamous cell of head and neck
Drug Therapy
Therapeutics

Keywords

  • Head and neck neoplasms
  • Ispinesib
  • Kinesin spindle protein
  • Phase II
  • Squamous
  • hsEg5

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. / Tang, Patricia A.; Siu, Lillian L.; Chen, Eric X.; Hotte, Sebastien J.; Chia, Stephen; Schwarz, James K; Pond, Gregory R.; Johnson, Caitlin; Colevas, A. Dimitrios; Synold, Timothy W.; Vasist, Lakshmi S.; Winquist, Eric.

In: Investigational New Drugs, Vol. 26, No. 3, 01.06.2008, p. 257-264.

Research output: Contribution to journalArticle

Tang, PA, Siu, LL, Chen, EX, Hotte, SJ, Chia, S, Schwarz, JK, Pond, GR, Johnson, C, Colevas, AD, Synold, TW, Vasist, LS & Winquist, E 2008, 'Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck', Investigational New Drugs, vol. 26, no. 3, pp. 257-264. https://doi.org/10.1007/s10637-007-9098-8
Tang, Patricia A. ; Siu, Lillian L. ; Chen, Eric X. ; Hotte, Sebastien J. ; Chia, Stephen ; Schwarz, James K ; Pond, Gregory R. ; Johnson, Caitlin ; Colevas, A. Dimitrios ; Synold, Timothy W. ; Vasist, Lakshmi S. ; Winquist, Eric. / Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. In: Investigational New Drugs. 2008 ; Vol. 26, No. 3. pp. 257-264.
@article{f3f04733b896477f99da6c91eea3e635,
title = "Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck",
abstract = "Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy. A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC). Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days. Twenty-one patients were enrolled onto this study with a target stage I sample size of 19. Of 20 evaluable patients, no objective responses were seen and stable disease > 2 cycles was observed in five patients (25{\%}). The median time to progression was 1.4 (95{\%} CI 1.3-2.3) months, median survival was 3.5 (95{\%} CI 2.8-7.8) months, and 1 year overall survival was 20{\%} (95{\%} CI 8.3-48.1{\%}). The most frequent attributable grades III-V adverse events were neutropenia (60{\%} of patients) and leukopenia (55{\%}). The pharmacokinetic profile was consistent with results from phase I studies. Archival tissues (n = 14) demonstrated low to moderate KSP expression by immunohistochemistry. In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule.",
keywords = "Head and neck neoplasms, Ispinesib, Kinesin spindle protein, Phase II, Squamous, hsEg5",
author = "Tang, {Patricia A.} and Siu, {Lillian L.} and Chen, {Eric X.} and Hotte, {Sebastien J.} and Stephen Chia and Schwarz, {James K} and Pond, {Gregory R.} and Caitlin Johnson and Colevas, {A. Dimitrios} and Synold, {Timothy W.} and Vasist, {Lakshmi S.} and Eric Winquist",
year = "2008",
month = "6",
day = "1",
doi = "10.1007/s10637-007-9098-8",
language = "English (US)",
volume = "26",
pages = "257--264",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck

AU - Tang, Patricia A.

AU - Siu, Lillian L.

AU - Chen, Eric X.

AU - Hotte, Sebastien J.

AU - Chia, Stephen

AU - Schwarz, James K

AU - Pond, Gregory R.

AU - Johnson, Caitlin

AU - Colevas, A. Dimitrios

AU - Synold, Timothy W.

AU - Vasist, Lakshmi S.

AU - Winquist, Eric

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy. A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC). Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days. Twenty-one patients were enrolled onto this study with a target stage I sample size of 19. Of 20 evaluable patients, no objective responses were seen and stable disease > 2 cycles was observed in five patients (25%). The median time to progression was 1.4 (95% CI 1.3-2.3) months, median survival was 3.5 (95% CI 2.8-7.8) months, and 1 year overall survival was 20% (95% CI 8.3-48.1%). The most frequent attributable grades III-V adverse events were neutropenia (60% of patients) and leukopenia (55%). The pharmacokinetic profile was consistent with results from phase I studies. Archival tissues (n = 14) demonstrated low to moderate KSP expression by immunohistochemistry. In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule.

AB - Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy. A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC). Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days. Twenty-one patients were enrolled onto this study with a target stage I sample size of 19. Of 20 evaluable patients, no objective responses were seen and stable disease > 2 cycles was observed in five patients (25%). The median time to progression was 1.4 (95% CI 1.3-2.3) months, median survival was 3.5 (95% CI 2.8-7.8) months, and 1 year overall survival was 20% (95% CI 8.3-48.1%). The most frequent attributable grades III-V adverse events were neutropenia (60% of patients) and leukopenia (55%). The pharmacokinetic profile was consistent with results from phase I studies. Archival tissues (n = 14) demonstrated low to moderate KSP expression by immunohistochemistry. In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule.

KW - Head and neck neoplasms

KW - Ispinesib

KW - Kinesin spindle protein

KW - Phase II

KW - Squamous

KW - hsEg5

UR - http://www.scopus.com/inward/record.url?scp=42549088324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549088324&partnerID=8YFLogxK

U2 - 10.1007/s10637-007-9098-8

DO - 10.1007/s10637-007-9098-8

M3 - Article

VL - 26

SP - 257

EP - 264

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -